About: Imatinib-induced irreversible interstitial lung disease: A case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Imatinib-induced irreversible interstitial lung disease: A case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Imatinib-induced irreversible interstitial lung disease: A case report
Creator	Zhang, Ping Huang, Jingfeng Jin, Fangfang Ouyang, Guifang Pan, Jiaohai
source	Medline; PMC
abstract	RATIONALE: Imatinib mesylate (imatinib) is a classic tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Although it is well tolerated by most patients and helps in the achievement of complete remission, a few rare imatinib-associated adverse effects such as pulmonary interstitial fibrosis have been reported. Because of its rareity, the clinical features of imatinib-induced interstitial lung disease (ILD) remain unclear. PATIENT CONCERNS: A 49-year-old Chinese man with chronic myeloid leukemia received oral treatment with imatinib and initially exhibited a good response. However, he presented with cough and fever 9 months after treatment initiation. DIAGNOSES: Pulmonary computed tomography indicated diffuse interstitial fibrosis in both lungs. All tests for possible infectious pathologies provided negative results. INTERVENTIONS: The patient was diagnosed with interstitial pneumonia and treated with antibiotics; however, there was no improvement. On the basis of a suspicion of imatinib-induced ILD, imatinib was discontinued and prednisone treatment was initiated. OUTCOMES: The patient's symptoms ameliorated with treatment, and imatinib was reintroduced. However, he developed cough and dyspnea again, and his treatment was switched to nilotinib as a second-line regimen. He was regularly monitored, and although his clinical symptoms ameliorated, computed tomography performed 29 months after he was diagnosed with ILD showed irreversible pulmonary interstitial fibrosis without progression. LESSONS: Clinicians should consider the possibility of severe irreversible ILD and carefully monitor patients receiving imatinib treatment.
has issue date	2019-02-22(xsd:dateTime)
bibo:doi	10.1097/md.0000000000014402
bibo:pmid	30813141
has license	cc-by-nc-nd
sha1sum (hex)	e8c88bae765a67eb93e119820caa702994e13c1d
schema:url	https://doi.org/10.1097/md.0000000000014402
resource representing a document's title	Imatinib-induced irreversible interstitial lung disease: A case report
has PubMed Central identifier	PMC6407980
has PubMed identifier	30813141
schema:publication	Medicine (Baltimore)
resource representing a document's body	covid:e8c88bae765a67eb93e119820caa702994e13c1d#body_text
is schema:about of	named entity 'interstitial lung disease' named entity 'case report' named entity 'TREAT' named entity 'CLASSIC' named entity 'ASSOCIATED' named entity 'PATIENTS' named entity 'TYROSINE KINASE INHIBITOR' named entity 'UNCLEAR' named entity 'ITS' named entity 'INTERSTITIAL LUNG DISEASE' named entity 'REPORTED' named entity 'USED' named entity 'CASE REPORT' named entity 'INTERSTITIAL LUNG DISEASE' named entity 'IS A' named entity 'HELPS' named entity 'IRREVERSIBLE' named entity 'INDUCED' named entity 'IMATINIB' named entity 'CLINICAL FEATURES' named entity 'IMATINIB MESYLATE' named entity 'INDUCED' named entity 'CHRONIC MYELOID LEUKEMIA' named entity 'IMATINIB' named entity 'RARE' named entity 'ACHIEVEMENT' named entity 'ADVERSE EFFECTS' named entity 'COMPLETE REMISSION' named entity 'RATIONALE' named entity 'PULMONARY INTERSTITIAL FIBROSIS' named entity 'HAVE' covid:arg/e8c88bae765a67eb93e119820caa702994e13c1d named entity 'helps' named entity 'interstitial lung disease' named entity 'tyrosine kinase inhibitor' named entity 'complete remission' named entity 'imatinib' named entity 'Imatinib mesylate' named entity 'adverse effects' named entity 'hyperplasia' named entity 'imatinib' named entity 'Imatinib' named entity 'reverse transcription polymerase chain reaction' named entity 'rheumatism' named entity 'Imatinib' named entity 'diffusing capacity' named entity 'imatinib' named entity 'prednisone' named entity 'relapse' named entity 'Lung function tests' named entity 'imatinib' named entity 'prednisone' named entity 'cough' named entity 'lungs' named entity 'lung function' named entity 'antibody' named entity 'nilotinib' named entity 'upper lobes' named entity 'cough' named entity 'Nilotinib' named entity 'rechallenge' named entity 'cell injury' named entity 'Mycoplasma pneumoniae' named entity 'lung' named entity 'prednisone' named entity 'antibody' named entity 'imatinib' named entity 'second-line treatment' named entity 'imatinib' named entity 'cough' named entity 'lungs' named entity 'imatinib' named entity 'Prednisone' named entity 'tumors' named entity 'mmol' named entity 'EBV' named entity 'CML'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software